Combining biomarkers for prognostic modelling of Parkinson’s disease

By Raquel Real, PhD, Ed Jabbari, Roger Barker, PhD, Nicholas Wood, PhD, John Hardy, PhD, Huw Morris, Christine Girges, Viorica Chelban, Katherine A Grosset, John Woodside, Manuela Tan, Tong Guo, Michael Lawton, Amanda Heslegrave, Nirosen Vijiaratnam, Ben-Shlomo Yoav, Thomas Foltynie, Henry Houlden, Henrik Zetterberg, Dilan Athauda, Nigel Williams and Donald Grosset
Published July 12, 2022
View Published Article View Preprint

Output Details

Preprint November 2, 2021

Published July 12, 2022

Description
Patients with Parkinson’s disease (PD) have variable rates of progression. More accurate prediction of progression could improve selection for clinical trials. Although some variance in clinical progression can be predicted by age at onset and phenotype, we hypothesise that this can be further improved by blood biomarkers. We evaluated the relationship between serum NfL and baseline and longitudinal clinical measures as well as patients’ genetic (GBA and APOE) status.
Identifier (DOI)
10.1136/jnnp-2021-328365
Tags
  • APOE (Apolipoprotein E)
  • Biomarkers
  • Blood
  • DNA
  • GBA (Glucocerebrosidase)
  • Genotyping
  • Motor symptoms
  • NfL (Neurofilament light)
  • Original Research
  • Prognostic modeling
  • SNPs (Single Nucleotide Polymorphisms)
Team
Team Hardy
Program
Collaborative Research Network
Theme
PD Functional Genomics

Meet the Authors

  • User avatar fallback logo

    Raquel Real, PhD

    Key Personnel: Team Hardy, 

    University College London

  • Ed Jabbari

    Key Personnel: Team Hardy, 

    University College London

  • Roger Barker, PhD

    Co-PI (Core Leadership): Team Jakobsson, 

    University of Cambridge

  • Nicholas Wood, PhD

    Lead PI (Core Leadership): Team Wood, 

    University College London

  • John Hardy, PhD

    Lead PI (Core Leadership): Team Hardy, 

    University College London

  • Huw Morris

    Collaborating PI: Team Hardy, 

    University College London

  • User avatar fallback logo

    Christine Girges

  • User avatar fallback logo

    Viorica Chelban

  • User avatar fallback logo

    Katherine A Grosset

  • User avatar fallback logo

    John Woodside

  • User avatar fallback logo

    Manuela Tan

  • User avatar fallback logo

    Tong Guo

  • User avatar fallback logo

    Michael Lawton

  • User avatar fallback logo

    Amanda Heslegrave

  • User avatar fallback logo

    Nirosen Vijiaratnam

  • User avatar fallback logo

    Ben-Shlomo Yoav

  • User avatar fallback logo

    Thomas Foltynie

  • User avatar fallback logo

    Henry Houlden

  • User avatar fallback logo

    Henrik Zetterberg

  • User avatar fallback logo

    Dilan Athauda

  • User avatar fallback logo

    Nigel Williams

  • User avatar fallback logo

    Donald Grosset

Related Research

SNP Genotyping and ApoE Genotyping

Protocol outlines DNA extraction from blood, quality control, SNP, and APOE genotyping. Adapted from PRoBaND SNP Genotyping and ApoE Genotyping Protocol by Malek et al. for Parkinson's Disease study.

View Protocol

huw-morris-lab/PDD_GWSS

The manuscript by Real et al. investigates the relationship between LRP1B and APOE loci and the onset of Parkinson’s disease dementia, utilizing specific code for analysis.

View Code

Association between the LRP1B and APOE loci and the development of Parkinson’s disease dementia

Genetic analysis of 3,964 PD cases revealed APOE-ϵ4 allele and new loci as risk factors for PD dementia progression, implicating amyloid pathway in PDD development and potential for amyloid-targeting therapy.

View Article
View More Outputs
Aligning Science Across Parkinson's
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.